Literature DB >> 31655173

Supermicrosurgical Lymphaticovenous Anastomosis as Alternative Treatment Option for Moderate-to-Severe Lower Limb Lymphedema.

Johnson Chia-Shen Yang1, Shao-Chun Wu2, Wei-Che Lin3, Min-Hsien Chiang2, Pi-Ling Chiang3, Ching-Hua Hsieh4.   

Abstract

BACKGROUND: Supermicrosurgical lymphaticovenous anastomosis (LVA) alleviates lymphedema by draining stagnant lymph from the lymphatic vessels into the venous system. Nevertheless, LVA is believed to be unsuitable for treating moderate-to-severe lymphedema presenting diffuse-pattern dermal backflow (DB). Dermal backflow is considered to be the sign of superficial lymphatic functional failure that renders LVA ineffective. Based on a current algorithm, a more invasive vascularized lymph node flap transfer is recommended instead of LVA. This retrospective study aimed to further investigate and possibly challenge this concept. STUDY
DESIGN: One-hundred patients with unilateral lymphedematous lower limbs who underwent LVA were included. Patients were divided into Group I (10 patients with mild lymphedema) and Group II (90 patients with moderate-to-severe lymphedema). Demographic data and intraoperative findings were recorded. The post-LVA volume reductions by magnetic resonance volumetry were recorded and analyzed.
RESULTS: Preoperatively, significant differences were found in BMI (20.6 vs 26.0 kg/m2, p = 0.004) and the volume gained in the lymphedematous limb (396.8 mL vs 1,056.8 mL, p = 0.005) between Groups I and II. Postoperatively, a significant median post-LVA volume reduction (-282.0 mL vs -763.5 mL, p = 0.022) was found in Group II. However, there were no differences in the percentages of post-LVA volume reduction (-43.8% vs -36.4%, p = 0.793) in Groups I and II.
CONCLUSIONS: The use of supermicrosurgical LVA is as effective at treating moderate-to-severe lymphedema as milder lymphedema. The indication for LVA should be broadened to include such cases.
Copyright © 2019 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31655173     DOI: 10.1016/j.jamcollsurg.2019.10.007

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  6 in total

1.  Effect of Lymphaticovenous Anastomosis on Muscle Edema, Limb, and Subfascial Volume in Lower Limb Lymphedema: MRI Studies.

Authors:  Johnson Chia-Shen Yang; Shao-Chun Wu; Yu-Ming Wang; Sheng-Dean Luo; Spencer Chia-Hao Kuo; Peng-Chen Chien; Pei-Yu Tsai; Ching-Hua Hsieh; Wei-Che Lin
Journal:  J Am Coll Surg       Date:  2022-04-18       Impact factor: 6.532

2.  Optimizing Treatment of Breast Cancer Related Lymphedema Using Combined DIEP Flap and Lymphedema Surgery.

Authors:  Edward I Chang
Journal:  Arch Plast Surg       Date:  2022-04-06

3.  Lymphaticovenous Anastomosis for Treating Secondary Lower Limb Lymphedema in Older Patients-A Retrospective Cohort Study.

Authors:  Johnson Chia-Shen Yang; Yu-Ming Wang; Shao-Chun Wu; Wei-Che Lin; Peng-Chen Chien; Pei-Yu Tsai; Ching-Hua Hsieh; Sheng-Dean Luo
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

4.  Two Non-gadolinium-based, Innovative Approaches to Preoperative Lymphangiography.

Authors:  Christine U Lee; James F Glockner; Gina K Hesley; Nathan J Brinkman; Nho V Tran
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-04-22

5.  Recovery of Dysregulated Genes in Cancer-Related Lower Limb Lymphedema After Supermicrosurgical Lymphaticovenous Anastomosis - A Prospective Longitudinal Cohort Study.

Authors:  Johnson Chia-Shen Yang; Lien-Hung Huang; Shao-Chun Wu; Yi-Chan Wu; Chia-Jung Wu; Chia-Wei Lin; Pei-Yu Tsai; Peng-Chen Chien; Ching-Hua Hsieh
Journal:  J Inflamm Res       Date:  2022-02-04

6.  Outcomes of Lymphovenous Anastomosis for Lower Extremity Lymphedema: A Systematic Review.

Authors:  Erik M Verhey; Lyndsay A Kandi; Yeonsoo S Lee; Bryn E Morris; William J Casey; Alanna M Rebecca; Lisa A Marks; Michael A Howard; Chad M Teven
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-10-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.